DE60013764D1 - Behandlung und vorbeugung von durch reaktive sauerstoffmetabolite verursachten zellschäden - Google Patents

Behandlung und vorbeugung von durch reaktive sauerstoffmetabolite verursachten zellschäden

Info

Publication number
DE60013764D1
DE60013764D1 DE60013764T DE60013764T DE60013764D1 DE 60013764 D1 DE60013764 D1 DE 60013764D1 DE 60013764 T DE60013764 T DE 60013764T DE 60013764 T DE60013764 T DE 60013764T DE 60013764 D1 DE60013764 D1 DE 60013764D1
Authority
DE
Germany
Prior art keywords
reactive oxygen
damage caused
prevention
treatment
roms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60013764T
Other languages
English (en)
Other versions
DE60013764T2 (de
Inventor
Kristoffer Hellstrand
Svante Hermodsson
R Gehlsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxim Pharmaceuticals Inc
Original Assignee
Maxim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxim Pharmaceuticals Inc filed Critical Maxim Pharmaceuticals Inc
Publication of DE60013764D1 publication Critical patent/DE60013764D1/de
Application granted granted Critical
Publication of DE60013764T2 publication Critical patent/DE60013764T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE60013764T 1999-01-08 2000-01-07 Behandlung und vorbeugung von durch reaktive sauerstoffmetabolite verursachten zellschäden Expired - Fee Related DE60013764T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/227,455 US6242473B1 (en) 1999-01-08 1999-01-08 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US227455 1999-01-08
PCT/US2000/000314 WO2000040241A2 (en) 1999-01-08 2000-01-07 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage

Publications (2)

Publication Number Publication Date
DE60013764D1 true DE60013764D1 (de) 2004-10-21
DE60013764T2 DE60013764T2 (de) 2005-09-29

Family

ID=22853182

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60013764T Expired - Fee Related DE60013764T2 (de) 1999-01-08 2000-01-07 Behandlung und vorbeugung von durch reaktive sauerstoffmetabolite verursachten zellschäden

Country Status (16)

Country Link
US (6) US6242473B1 (de)
EP (2) EP1410798A3 (de)
JP (1) JP2002534384A (de)
KR (1) KR20010101416A (de)
CN (1) CN1203851C (de)
AT (1) ATE275954T1 (de)
AU (1) AU768526B2 (de)
CA (1) CA2358851A1 (de)
DE (1) DE60013764T2 (de)
ES (1) ES2228453T3 (de)
HK (1) HK1040923B (de)
IL (1) IL143970A0 (de)
PT (1) PT1140077E (de)
TW (1) TWI248816B (de)
WO (1) WO2000040241A2 (de)
ZA (1) ZA200105165B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8586298A (en) * 1997-07-25 1999-02-16 University Of Massachusetts Designed protein pores as components for biosensors
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6270781B1 (en) * 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
AU2002302535A1 (en) * 2001-04-13 2002-10-28 Axxima Pharmaceuticals Ag Gastrointestinal glutathione peroxidase in hepatitis c virus infections
US7341717B2 (en) * 2001-04-13 2008-03-11 Gpc Biotech Ag Therapeutic targets for treatment of HCV infections, methods of treating HCV infections and compounds useful therefor
DE60229371D1 (de) * 2001-05-02 2008-11-27 Brni Neurosciences Inst Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung
IL160928A0 (en) * 2001-10-19 2004-08-31 Maxim Pharm Inc Use of histamine to treat liver disease
EP1448127A1 (de) * 2001-11-06 2004-08-25 Maxim Pharmaceuticals, Inc. Zusammensetzungen für die behandlung von infektionskrankheiten
EP1536819A4 (de) * 2002-03-29 2007-10-17 Maxim Pharm Inc Nutzung der produktion von reaktiven sauerstoffmetaboliten (rom) und freisetzungshemmern zur behandlung und prävention von intraokularen schäden
EP1503819A4 (de) * 2002-05-08 2007-07-25 Univ California System und verfahren zur herstellung eines nichtablativen herzleitungsblocks
US20040106896A1 (en) * 2002-11-29 2004-06-03 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
ES2312780T3 (es) 2002-05-13 2009-03-01 Arexis Ab Afecciones autoinmunes y deficiencias de oxidasa nadph.
EP1380290A1 (de) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-Beta-Strukturweg und seine therapeutische Relevanz
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
US20040057983A1 (en) 2002-09-25 2004-03-25 David Schmidt Biomolecular wearable apparatus
US7317950B2 (en) * 2002-11-16 2008-01-08 The Regents Of The University Of California Cardiac stimulation system with delivery of conductive agent
WO2004045556A2 (en) * 2002-11-20 2004-06-03 Board Of Regents, The University Of Texas System Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens
GB0308382D0 (en) * 2003-04-10 2003-05-21 Univ Cambridge Tech Therapeutic methods and means
US7290197B2 (en) * 2003-06-03 2007-10-30 Quantum Corporation Correcting data using redundancy blocks
US20050171192A1 (en) * 2003-12-11 2005-08-04 Gehlsen Kurt R. Use of histamine to treat bone disease
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
EP1602926A1 (de) 2004-06-04 2005-12-07 University of Geneva Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
AU2006267177A1 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Methods for determining the effect of a treatment on the cross-beta structure content of a protein; selection of treatments and uses thereof
ATE554394T1 (de) 2005-07-13 2012-05-15 Crossbeta Biosciences Bv Cross-beta-struktur-bindende verbindungen
CA2623725A1 (en) * 2005-09-30 2007-04-12 Omp, Inc. Stable ascorbic acid compositions
JP2009084155A (ja) * 2006-01-16 2009-04-23 Kanazawa Univ レビー小体病治療薬及びレビー小体病予防薬
US8999933B2 (en) * 2006-01-18 2015-04-07 Biolitec Pharma Marketing Ltd Photodynamic cosmetic procedure and healing method
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US20070178058A1 (en) * 2006-02-02 2007-08-02 Ramirez Jose E Methods of using stable ascorbic acid compositions
US20070269534A1 (en) * 2006-02-02 2007-11-22 Ramirez Jose E Methods of treating skin to enhance therapeutic treatment thereof
EP2007800A1 (de) * 2006-03-17 2008-12-31 Crossbeta Biosciences B.V. Verfahren zur bindung von kreuz-beta-strukturen durch chaperone
EP2058001A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Steigerung der Immunogenizität von Antigenen
EP2058000A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung
US8602961B2 (en) * 2008-05-15 2013-12-10 Lifewave Products Llc Apparatus and method of stimulating elevation of glutathione levels in a subject
WO2010089712A2 (en) * 2009-02-05 2010-08-12 Lui, Jacqueline, C. Formulation for the treatment of hypoxia and related disorders
EP3406244B1 (de) 2009-04-15 2023-06-07 BMG Pharma S.p.A. Zusammensetzungen enthaltend zinkgluconat und taurin für schleimhaut- und hautbeschwerden
WO2014066672A1 (en) * 2012-10-26 2014-05-01 Beech Tree Labs, Inc. Method of treating muscular weakness comprising administering a composition comprising an effective amount of histamine and/or serotonin
EP4340838A1 (de) * 2021-05-19 2024-03-27 Alberto Paz Oral verabreichte zusammensetzungen zur krebsbehandlung

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636202A (en) * 1968-02-12 1972-01-18 Lewis A Klein Treatment of rheumatoid arthritis and related diseases
SU512764A1 (ru) * 1972-02-24 1976-05-05 Войсковая Часть 64688 Средство дл профилактики атеросклероза "аэровит"
US3898325A (en) * 1973-09-19 1975-08-05 American Lipids Corp Method and preparations for relieving pain and producing analgesia
US4704273A (en) * 1982-05-17 1987-11-03 Mcmichael John Methods and materials for treatment of rheumatoid arthritis
DE3239870A1 (de) * 1982-10-27 1984-05-03 Gert Dr.med. 8000 München Baumann Arzneimittel zur behandlung von chronischem und akutem herzversagen
US5268291A (en) 1983-01-19 1993-12-07 Genentech, Inc. Human t-PA production using vectors coding for DHFR protein
US4573996A (en) 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
IL74222A (en) * 1984-02-06 1988-07-31 Lilly Co Eli 6-substituted-4-dialkylamino tetrahydrobenz(c,d)indoles,their preparation and pharmaceutical compositions comprising them
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
JPH0717504B2 (ja) * 1985-03-09 1995-03-01 美浜 久春 血栓症予防及び治療用組成物
US5122127A (en) 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4843096A (en) * 1985-06-26 1989-06-27 Stiefel Laboratories, Inc. Treatment of acne
SU1394134A1 (ru) * 1986-02-27 1988-05-07 Тернопольский государственный медицинский институт Способ исследовани секреторной функции желудка
DE3616923A1 (de) * 1986-05-20 1987-11-26 Nattermann A & Cie Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on
JPS6396123A (ja) * 1986-10-13 1988-04-27 Kuraray Co Ltd ビタミンａ酸亜鉛塩を含有する抗炎症剤
US5166134A (en) * 1986-12-24 1992-11-24 John Lezdey Treatment of allergic rhinitis
US4886665A (en) * 1987-03-11 1989-12-12 Arcopharma Ltd. Compositions of oats and nettle extracts to be used as a food additive or pharmaceutical preparation in human health care
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
DE3720493A1 (de) * 1987-06-20 1989-01-26 Nattermann A & Cie Arzneizubereitungen mit mikronisierten ebselen-kristallen
US4943435A (en) 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4839174A (en) 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US5284647A (en) 1988-03-18 1994-02-08 Schering Aktiengesellschaft Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them
US5094953A (en) 1988-03-21 1992-03-10 Genentech, Inc. Human tissue plasminogen activator variants
US5214156A (en) * 1988-03-25 1993-05-25 The Upjohn Company Therapeutically useful tetralin derivatives
US5674706A (en) * 1988-05-06 1997-10-07 Chiron Corporation High level expression of proteins in yeast
DE3821392A1 (de) * 1988-06-24 1989-12-28 Nattermann A & Cie Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on (ebselen)
DE3831888A1 (de) * 1988-09-20 1990-03-29 Troponwerke Gmbh & Co Kg Arzneimittel zur behandlung von apoplexia cerebri
US4908213A (en) 1989-02-21 1990-03-13 Schering Corporation Transdermal delivery of nicotine
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
IT1230140B (it) * 1989-05-03 1991-10-14 Fidia Spa Derivati della serina, loro processo di preparazione e impiego in terapia umana
US5637479A (en) * 1989-06-23 1997-06-10 The Trustees Of The University Of Pennsylvania Method of modulating DNA binding activity of recombinant α-1 antichymotrypsin and other serine protease inhibitors
US5723316A (en) * 1989-06-23 1998-03-03 Trustees Of The University Of Pennsylvania α-1-antichymotrypsin analogues having chymase inhibiting activity
US5674708A (en) * 1989-06-23 1997-10-07 Trustees Of The University Of Pennsylvania α-1-antichymotrypsin analogues having elastase inhibitory activity
US5134154A (en) * 1989-10-20 1992-07-28 Merrell Dow Pharmaceuticals Inc. Phenoxy-heterocyclic compounds
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
US5215965A (en) * 1990-10-02 1993-06-01 John Lezdey Treatment of inflammation
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
DE4039631A1 (de) * 1990-12-12 1992-06-17 Troponwerke Gmbh & Co Kg Neuroprotektive kombination
US5679337A (en) 1991-06-14 1997-10-21 Professional Pharmaceutical, Inc. Method and composition for topical treatment of Aphthous stomatitis histamine using phosphate as active ingredient
KR100256715B1 (ko) 1991-08-26 2000-05-15 스티븐 에프. 웨인스톡 치료제의 설하 또는 구강 투여를 위한 조성물
JPH05163160A (ja) * 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
GB9200623D0 (en) * 1992-01-13 1992-03-11 Bayer Ag Benzofuranyl and thiophenyl-methylthio-alkanecarboxylic acid derivatives
US5244916A (en) * 1992-01-31 1993-09-14 The Scripps Research Institute Inhibition of respiratory burst using posttranslational modification inhibitors
JP2927961B2 (ja) * 1992-02-07 1999-07-28 エム． クリグマン，アルバート 炎症性皮膚病の治療方法
JPH05213763A (ja) * 1992-02-10 1993-08-24 Sanwa Kagaku Kenkyusho Co Ltd 易吸収活性化カルシウム製剤
US5219888A (en) * 1992-03-31 1993-06-15 American Cyanamid Company Use of retinoids for the treatment of coronary artery disease
CA2075517C (en) 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
SE513429C2 (sv) 1992-06-03 2000-09-11 Syntello Inc Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer
DK0643772T3 (da) 1992-06-03 1998-02-02 Genentech Inc Glycosyleringsvarianter af vævsplasminogenaktivator med forbedrede terapeutiske egenskaber
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
IT1260155B (it) * 1992-08-03 1996-03-28 Fidia Spa Uso terapeutico della fosforil-l-serina-n-acil-sfingosina
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
US5376633A (en) * 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
US5834509A (en) * 1992-12-07 1998-11-10 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
FR2699821A1 (fr) * 1992-12-24 1994-07-01 Pichot Eric Traitement homéopathique préventif des maladies cardio-vasculaires (athérome, athérothrombomatose, infarctus du myocarde).
US5474527A (en) 1993-03-29 1995-12-12 Bettinger; David S. Positive displacement transdermal system
US5686436A (en) * 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
US5457129A (en) * 1993-05-17 1995-10-10 Research Development Foundation Inhibition of nitric oxide production by retinoic acid
EP0703917A1 (de) * 1993-06-17 1996-04-03 Novartis AG Indolcarbazolverbindung verwendbar als proteinkinase c inhibitor
US5549906A (en) 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5726155A (en) 1993-08-02 1998-03-10 The Scripps Research Institute Regulation of oxidative burst using LMWG-derived peptides and analogs
JP3193205B2 (ja) * 1993-08-09 2001-07-30 日本臓器製薬株式会社 好酸球増多抑制剤
DE4329776A1 (de) * 1993-09-03 1995-03-09 Sandoz Ag Naphthoxazine, ihre Herstellung und Verwendung
US5502063A (en) * 1993-10-11 1996-03-26 Sanofi 1-halopyridin-4-amino-4-alkylpiperidines
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
GB2285047B (en) * 1993-12-21 1998-04-15 Yamanouchi U K Ltd Polypeptides which inhibit the NADPH oxidase complex
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
WO1995026953A1 (fr) * 1994-03-30 1995-10-12 Yoshitomi Pharmaceutical Industries, Ltd. Compose d'acide benzoïque et son utilisation comme medicament
JPH07313180A (ja) * 1994-05-19 1995-12-05 Mercian Corp 新規ポリエン化合物
WO1996001107A1 (en) * 1994-07-06 1996-01-18 Bo Arne Hofmann Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
JPH10504304A (ja) 1994-08-08 1998-04-28 マキシム ファーマシューティカルズ，インコーポレイテッド ナチュラルキラー細胞活性化物質と過酸化水素スカベンジャーまたは過酸化水素阻害物質とを用いるナチュラルキラー細胞の活性増強
GB9416921D0 (en) * 1994-08-22 1994-10-12 Conway Gitta C A nutritional preparation
US5502080A (en) * 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
FR2727682A1 (fr) * 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
US5804203A (en) 1994-12-21 1998-09-08 Cosmederm Technologies Topical product formulations containing strontium for reducing skin irritation
US5489611A (en) * 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5830453A (en) * 1995-05-19 1998-11-03 Emory University Use of IL-13 to induce 15-lipoxygenase
US5637497A (en) * 1995-06-28 1997-06-10 Alcon Laboratories, Inc. Apparatus and method for cleaning and disinfecting contact lenses
FR2739777B1 (fr) * 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
US5763496A (en) * 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
BR9509985A (pt) * 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
US5597585A (en) * 1995-12-26 1997-01-28 Williams; Andrew H. Vitamin/mineral composition
AU2611297A (en) * 1996-04-12 1997-11-07 Eli Lilly And Company Bisindoles for treating pain or nociception
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
US6071942A (en) * 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
AU2434297A (en) * 1996-05-23 1997-12-09 Alcon Laboratories, Inc. The use of 5-ht1b/1d agonists to treat ocular pain
TW336325B (en) * 1996-05-24 1998-07-11 Electrocopper Products Ltd Copper wire and process for making copper wire
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
US5939460A (en) * 1996-07-08 1999-08-17 Idun Pharmaceuticals, Inc. Method of inhibiting NADPH oxidase
JPH10120700A (ja) * 1996-10-17 1998-05-12 Takeda Chem Ind Ltd ヒスタミン産生増大因子およびその用途
WO1998031384A1 (en) * 1997-01-22 1998-07-23 The Wistar Institute Of Anatomy & Biology Methods and compositions using interleukin-13 for enhancing immune responses
CA2341742A1 (en) * 1998-08-24 2000-03-02 Maxim Pharmaceuticals, Inc. Activation and protection of t-cells (cd4+ and cd8+) using an h2 receptor agonist and other t-cell activating agents
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6270781B1 (en) * 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors

Also Published As

Publication number Publication date
IL143970A0 (en) 2002-04-21
PT1140077E (pt) 2005-01-31
EP1140077A2 (de) 2001-10-10
US6730692B2 (en) 2004-05-04
CA2358851A1 (en) 2000-07-13
DE60013764T2 (de) 2005-09-29
US20030017145A1 (en) 2003-01-23
WO2000040241A2 (en) 2000-07-13
AU768526B2 (en) 2003-12-18
US6462067B1 (en) 2002-10-08
CN1203851C (zh) 2005-06-01
CN1342079A (zh) 2002-03-27
EP1140077B1 (de) 2004-09-15
US20040191239A1 (en) 2004-09-30
AU2407500A (en) 2000-07-24
WO2000040241A3 (en) 2000-11-30
HK1040923B (zh) 2005-04-01
ATE275954T1 (de) 2004-10-15
EP1410798A2 (de) 2004-04-21
TWI248816B (en) 2006-02-11
US20020150565A1 (en) 2002-10-17
JP2002534384A (ja) 2002-10-15
US6242473B1 (en) 2001-06-05
KR20010101416A (ko) 2001-11-14
HK1040923A1 (en) 2002-06-28
EP1410798A3 (de) 2004-10-13
US20010023256A1 (en) 2001-09-20
ES2228453T3 (es) 2005-04-16
ZA200105165B (en) 2002-06-12
US6407133B2 (en) 2002-06-18

Similar Documents

Publication Publication Date Title
DE60013764D1 (de) Behandlung und vorbeugung von durch reaktive sauerstoffmetabolite verursachten zellschäden
WO2002057415A3 (en) Method for altering cell fate
WO2004053096A3 (en) Engineering three-dimensional tissue structures using differentiating embryonic stem cells
EP2767291A3 (de) Behandlung der Glykogenspeicherkrankheit Typ II
WO2002040630A3 (en) Process of decellularizing biological matrices and acellular biological matrices useful in tissue engineering
ES2168006T3 (es) Factor neurotrofico ciliar modificado, metodo de fabricacion y metodos de utilizacion.
FR2815627B1 (fr) Procede pour ameliorer la resistance mecanique notamment "aux jeunes ages" des matrices cimentaires, matrices cimentaires ainsi obtenues et leurs utilisations
DE69605865D1 (de) Poröser ionenaustauscher und methode fur herstellung von entionisiertem wasser
DE69525151T2 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
WO2006138330A3 (en) Tissue treatment methods
FR2797186B1 (fr) Procede d'extraction d'un principe actif a partir de levures, notamment pour le traitement des rides, principe actif obtenu, compositions cosmetiques et traitement adaptes
DE69601814T2 (de) Verfahren zur hydrometallurgischen und elektrochemischen Behandlung der aktiven Masse verbrauchter Bleibatterien zwecks Herstellung von Elektrolyt-Blei und Elementar-Schwefel
DE69534632T2 (de) Clotrimazol-Metaboliten bei der Behandlung von Sichelzellenkrankheit
FI941764A (fi) Menetelmä lignoselluloosapitoisen massan valkaisemiseksi
RS50129B (sr) Optički aktivan derivat piridil-4h-1,2,4-oksadiazina i njegova upotreba u proizvodnji lekova za tretiranje vaskularnih bolesti
WO2003078607A3 (en) Tissue specific signal-plexes to dedifferentiate and redifferentiate cells
FI20000511A (fi) Työliuoksen regenerointi vetyperoksidin valmistusprosessissa
ATE345121T1 (de) Verwendung von konjugierter linolsäure zur behandlung der erkältung
ES2138577T1 (es) Procedimiento de realizacion de un piso de filtro para el tratamiento de las aguas.
SE0100977L (sv) Blekning av massa med klordioxid
SE0300148D0 (sv) Filter structure
WO2001034553A3 (en) 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
TR200003084T2 (tr) Paroxetine askorbat
SU1487903A1 (ru) Способ тимпанопластики
DE59808160D1 (de) Zusammensetzung zur behandlung von gegerbtem leder, sowie ihre herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee